Patterns of response of breast cancer after neoadjuvant chemotherapy according to molecular subtype
pCR rates varied markedly among molecular subtypes, being highest in HER2-enriched tumors and lowest in Luminal A. These findings support molecular subtype as a key determinant of treatment response and highlight its role in guiding neoadjuvant treatment strategies.
Authors
- Hazem Assi (ORCID: https://orcid.org/0000-0002-8483-0938)
- Jaber Abbas (ORCID: https://orcid.org/0000-0002-4606-5796)
- Eman Sbaity (ORCID: https://orcid.org/0000-0003-2969-4782)
- Sali F. Sarkis
- Najla Fakhruddin (ORCID: https://orcid.org/0000-0003-2719-9921)
- Malak Ghezzawi (ORCID: https://orcid.org/0009-0009-0702-0139)
- Vahé Panossian
- Anthony Haddad (ORCID: https://orcid.org/0000-0001-6698-2439)
- Yara Zebian
- Mohamad Hadi El Charif (ORCID: https://orcid.org/0000-0002-0629-1449)
- Mazen A. Maktabi
- Lynn Lteif
- Mira Kheil (ORCID: https://orcid.org/0000-0001-7426-5923)
- Ziad Salem
Institutions
- American University of Beirut (LB)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-11-26
- DOI
- https://doi.org/10.3389/fonc.2025.1670594
- Citations
- 2
- Primary Topic
- Breast Cancer Treatment Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.87